Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Akebia Therapeutics Ownership Summary


Akebia Therapeutics is owned by 46.82% institutional investors, 3.56% insiders, and 49.62% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.16% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkebia Therapeutics46.82%3.56%49.62%
SectorHealthcare Stocks 42.52%10.82%46.66%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de18.80M7.16%$51.32M
Vanguard group15.55M5.92%$42.44M
Blackrock11.64M5.68%$11.87M
State street11.84M4.51%$32.34M
Alerce investment management5.75M2.73%$10.92M
Geode capital management6.18M2.36%$16.89M
Morgan stanley4.32M1.64%$11.78M
Renaissance3.95M1.51%$10.79M
Ubs group3.65M1.39%$9.95M
Qube research3.21M1.22%$8.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alerce investment management5.75M19.23%$10.92M
Bioimpact capital2.89M1.29%$7.89M
Affinity asset advisors2.45M0.58%$6.69M
Nantahala capital management2.00M0.19%$5.46M
Orchard capital management53.51K0.13%$146.08K
Diametric capital, lp87.62K0.09%$239.21K
Round rock advisors143.25K0.07%$426.88K
Unified investment management18.00K0.05%$49.14K
Entrypoint capital44.45K0.05%$121.35K
Gsa capital partners llp182.44K0.04%$498.00K

Top Buyers

HolderShares% AssetsChange
Blackrock11.64M0.00%9.10M
State street11.84M0.00%3.85M
Ubs group3.65M0.00%3.01M
Invesco2.40M0.00%2.02M
Citigroup1.92M0.00%1.78M

Top Sellers

HolderShares% AssetsChange
Aigh capital management---2.92M
Goldman sachs group1.77M0.00%-2.17M
Great point partners---1.99M
Monashee investment management---1.50M
Eam investors---1.45M

New Positions

HolderShares% AssetsChangeValue
Swiss national bank509.30K0.00%509.30K$1.39M
Assenagon asset management426.77K0.00%426.77K$1.17M
Jump financial355.84K0.01%355.84K$971.45K
Voleon capital management lp211.77K0.01%211.77K$578.12K
Freestone grove partners lp202.12K0.00%202.12K$551.79K

Sold Out

HolderChange
Stephens consulting-6.00
Capital performance advisors llp-68.00
Hexagon capital partners-186.00
Laurel wealth advisors-229.00
Redwood wealth management group-300.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202517212.42%122,932,54428.32%462.83%102-3.77%3454.55%
Jun 30, 20251628.72%108,281,33413.45%452.80%11119.35%23-11.54%
Mar 31, 202515019.05%95,500,61040.77%403.90%9434.29%2722.73%
Dec 31, 20241244.20%67,787,36714.05%324.04%7018.64%22-15.38%
Sep 30, 20241189.26%59,390,7035.52%283.74%599.26%268.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv7.79M2.96%-172.84K
Vanguard US Total Market Shares ETF5.95M2.52%-
iShares Russell 2000 ETF6.06M2.29%-
SPDR® S&P Biotech ETF3.09M1.17%6.91K
Vanguard Institutional Extnd Mkt Idx Tr2.59M0.99%-1.16M
Fidelity Small Cap Index2.50M0.94%312.83K
Foord Global Equity (Lux) A1.99M0.76%1.99M
iShares Russell 2000 Value ETF1.96M0.74%-
Foord Global Equity Class B1.83M0.70%1.83M
Nuveen Quant Small Cap Equity R61.79M0.68%-276.70K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 30, 2025Ostrowski Erik SVP, CFO, CBO & TreasurerSell$151.62K
Jun 09, 2025Malabre Richard C SVP, Chief Accounting OfficerSell$60.15K
Jun 04, 2025Malabre Richard C SVP, Chief Accounting OfficerSell$47.07K
Mar 03, 2025Butler John P. CEO and PresidentSell$84.93K
Mar 03, 2025Burke Steven Keith SVP, Chief Medical OfficerSell$13.07K

Insider Transactions Trends


DateBuySell
2025 Q2-3
2025 Q1-8
2024 Q2-2
2024 Q1-10
2023 Q3-1

AKBA Ownership FAQ


Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 46.82%, followed by 3.56% insiders and 49.62% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 45.24%, which Akebia Therapeutics exceeds.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock funding, inc. /de (18.8M shares, 7.16%), Vanguard group (15.55M shares, 5.92%), and Blackrock (11.64M shares, 5.68%). Together, they hold 18.76% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.23% of its assets in 5.75M Akebia Therapeutics shares, valued at 10.92M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akebia Therapeutics shares, with 2.96% of its total shares outstanding invested in 7.79M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools